Insight Conference
Sergio Pérez Rosal, M.D.
11:00am - 11:30am
Room: Auditorium


Psychedelic-Augmented Psychotherapy at the OVID Clinics- Concept, Experience and Outlook

The use of dissociative anesthetics like ketamine and esketamine has become popular in the field of psychiatry. There is a growing body of research validating its application in patients suffering from depression, anxiety, OCD, and even PTSD. However, treatment is not standardized. In most cases, the concept relies only on the pharmacological effects leaving out the importance and potential of combining psychotherapy with dosing sessions.

Based on recent findings on psychedelic-assisted psychotherapy and ketamine research, we have created a concept in which we combine the administration of an atypical psychedelic in sub-anesthetic levels with psychotherapeutic guidance and integration therapy. Our treatment plan harnesses the strengths of two proven methods and combines them, leading to a more significant effect than the sum of both approaches. With this approach we are able to provide psychedelic experiences facilitated through ketamine with the same respect and therapeutic guidance as a serotonergic substance therapy.

Standardization of ketamine-assisted therapy rooted in the methodology used in high-level classic psychedelic therapy research could lead to safer therapy, more efficient and significantly longer-lasting effect for a patient collective that has exhausted more established therapeutic models.


Director of the MIND Academy

Sergio Pérez Rosal, M.D.

MIND Foundation
View Speaker Profile